{"entity":{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","aka":[],"tldr":"Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval.","summary":"Nikhil Munshi was principal investigator of KarMMa, the pivotal trial showing the BCMA-directed CAR-T idecabtagene vicleucel produces responses in nearly three-quarters of heavily pretreated myeloma patients, leading to the first CAR-T approval in the disease, and of KarMMa-3 comparing it with standard regimens. His laboratory studies myeloma genomics and he led the meta-analysis establishing MRD negativity as a surrogate for survival.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene"}],"tags":["myeloma","car-t","genomics"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t","mrd-testing"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["karmma-3"],"people":[],"bottlenecks":[],"keyPapers":["paper-karmma-3-ide-cel-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Multiple myeloma","CAR T-cell therapy","Myeloma genomics","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene"}],"papers":[{"title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma (KarMMa)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2024850"},{"title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","journal":"JAMA Oncology","year":2017,"doi":"10.1001/jamaoncol.2016.3160"},{"title":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2213614","doi":"10.1056/NEJMoa2213614"}]},"route":"/people/nikhil-munshi/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/"}],"paper":[{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/"}]}}